Press Releases CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Market Closed - Hong Kong S.E. Other stock markets 04:08:03 2024-05-23 am EDT			5-day change	1st Jan Change
0.35 ^HKD	+4.48%		+6.06%	-64.65%

Apr. 23	Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	MT
Apr. 22	CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base	Mar. 04	AQ
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully	Nov. 07	AQ
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress	23-10-26	AQ
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	23-10-18	AQ
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China	23-10-16	AQ
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	23-10-09	AQ
CANbridge to Participate in Two Investor Conferences in September	23-09-07	AQ
CANbridge to Participate in the Jefferies 2023 Global Healthcare Conference	23-06-01	AQ
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI EMBARK Phase 2 Study in Biliary Atresia	23-05-30	AQ
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy annual Meeting	23-04-13	AQ
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme in China Reaches Full Enrollment	23-03-29	AQ
CANbridge Pharmaceuticals Announces CAN008 Phase 1/2 Glioblastoma Multiforme Abstract Accepted by the ESMO Sarcoma and Rare Cancers Congress	23-03-14	AQ
Article from Cloud-based Medicine Studio A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated	23-02-01	AQ
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China	23-01-19	AQ
CANbridge Consolidates Gene Therapy Portfolio	23-01-05	AQ
CANbridge Congratulates Mirum on EU Marketing Approval for Maralixibat/LIVMARLI to Treat Cholestatic Pruritis in Rare Liver Disease, Alagille Syndrome	22-12-21	AQ
CANbridge - Article from PhIRDABi Jingquan to encourage the R&D of drugs for rare diseases we need to study and formulate special policies that conform to the characteristics of rare diseases	22-11-02	AQ
CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy 29th Annual Congress	22-10-14	AQ
CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022	22-08-25	AQ
CANbridge Pharmaceuticals Inc. - First Patient Dosed in CAN108 EMBARK Phase 2 Study in Biliary Atresia in China, China Study is Part of Global EMBARK Study	22-07-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Press Releases

Filters